Back to top

crispr: Archive

Zacks Equity Research

Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies

Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.

VRTXNegative Net Change EDITNegative Net Change CRSPNegative Net Change ALXONegative Net Change